首頁 > 市場調查報告書 > 製藥

消化器孤兒藥

市場調查報告書

商品編碼

1535958

克隆氏症治療市場- 按治療（藥物{抗發炎藥、免疫抑制劑、抗生素、退燒藥}、營養治療、手術）、劑型（口服、腸胃外）、年齡層、最終用途、全球預測2024 - 2032

Crohns Disease Treatment Market - By Treatment (Medication {Anti-inflammatory Agents, Immunosuppressants, Antibiotics, Antipyretics}, Nutritional Therapy, Surgery), Dosage Form (Oral, Parenteral), Age Group, End-use, Global Forecast 2024 - 2032

出版日期: 2024年06月27日 | 出版商:

Global Market Insights Inc. | 英文 108 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在全球發炎性腸道疾病 (IBD) 盛行率不斷上升的推動下，克隆氏症治療市場預計 2024 年至 2032 年複合年成長率將達到 4%。根據克隆氏症和結腸炎基金會 2023 年的情況說明書，大約有 160 至 310 萬美國人受到 IBD 的影響。意識和診斷能力的提高導致更多病例被發現，從而增加了對有效治療的需求。醫學研究和技術的進步也帶來了新的療法和生物製劑，為患者帶來了希望。例如，2024年7月，FDA批准了Stelara（楊森免疫學）的成分ustekinumab-ttwe用於所有適應症，包括嚴重乾癬、乾癬性關節炎、克隆氏症和潰瘍性結腸炎。

此外，對個人化醫療的關注正在改變克隆氏症的治療方式。隨著對疾病病理生理學的了解不斷加深，治療方法也越來越適合個體的遺傳和分子特徵。這種方法提高了治療效果和患者治療效果，進一步推動市場成長。

整個克隆氏症治療產業根據治療、劑型、年齡層、最終用途和地區進行分類。

由於營養治療在控制症狀和改善患者預後方面發揮關鍵作用，因此到 2032 年將獲得巨大的關注。營養治療有助於解決吸收不良問題、維持適當的營養狀態並減少發炎。客製化飲食計劃，例如腸內營養和排除飲食，因其誘導緩解和補充藥物治療的潛力而日益受到認可。這種方法不僅支持整體健康和生活品質，而且還減少了對藥物的依賴，藥物可能會產生不利影響。

由於人們對疾病的認知不斷提高以及早期診斷的益處，兒科細分市場預計到 2032 年將佔據顯著的市場佔有率。兒科患者的克隆氏症帶來了獨特的挑戰，包括需要對發育中的身體安全有效的治療。研究的進步為兒童提供了量身定做的治療方法，包括針對生長和疾病管理的適合年齡的藥物和營養干預措施。對早期介入和個人化護理的日益重視正在推動對兒科患者專業治療和支援服務的需求。

受該地區疾病盛行率上升、醫療基礎設施改善以及人們對克隆氏症認知不斷提高的推動，亞太地區克隆氏症治療市場規模將在 2032 年大幅擴大。醫療保健服務範圍的擴大和醫療技術的投資正在促進先進治療方案的可用性，包括生物製劑和標靶治療。此外，該地區對研發的日益關注正在促進創新和提高護理品質。隨著經濟的持續發展和醫療保健系統的發展，亞太市場有望大幅成長。

產業生態系統分析
產業影響力
- 成長動力
  - 克隆氏症患者病率增加
  - 診斷技術的進步
  - 增加藥物開發的研究與開發活動
  - 提高人們對克隆氏症的認知
- 產業陷阱與挑戰
  - 疾病管理的複雜性
  - 缺乏治療方法
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按處理方式，2021 - 2032

主要趨勢
藥物
- 抗發炎劑
- 免疫抑制劑
- 抗生素和退燒藥
- 其他藥物
營養治療
手術

第 6 章：市場估計與預測：按劑型，2021 - 2032

主要趨勢
口服
注射用

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

主要趨勢
兒科
成人
老年科

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院和診所
家庭護理設置
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Biogen
Boehringer Ingelheim GmbH
Bristol Myerr Squibb
Eli Lilly and Company
Janssen Pharmaceuticals (Johnson & Johnson)
Merck & Co. Inc
Novartis AG
Pfizer, Inc.
Salix Pharmaceuticals, Inc.
Takeda Pharmaceutical Industries Limited
Viatris Inc. (Mylan N.V.)

簡介目錄

Product Code: 10038

Crohn's Disease Treatment Market is anticipated to record 4% CAGR during 2024-2032, backed by the increasing global prevalence of inflammatory bowel disease (IBD). According to the 2023 fact sheet by Crohn's & Colitis Foundation, around 1.6 to 3.1 million Americans are affected by IBD. Improved awareness and diagnostics are leading to more cases being identified, which boosts the demand for effective treatments. Advances in medical research and technology have also led to new therapies and biologics, offering hope for patients. For example, in July 2024, the FDA granted approval for ustekinumab-ttwe, a component of Stelara (Janssen Immunology), for all its indications, including severe psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Additionally, the focus on personalized medicine is changing how Crohn's disease is treated. As the understanding of the disease's pathophysiology improves, treatments are becoming more tailored to individual genetic and molecular profiles. This approach improves treatment effectiveness and patient outcomes, further driving market growth.

The overall Crohn's disease treatment industry is classified based on treatment, dosage form, age group, end-use, and region.

The nutritional therapy segment will gain significant traction through 2032, due to its critical role in managing symptoms and improving patient outcomes. Nutritional therapy helps address malabsorption issues, maintain proper nutritional status, and reduce inflammation. Customized dietary plans, such as enteral nutrition and exclusion diets, are increasingly recognized for their potential to induce remission and complement pharmacological treatments. This approach not only supports overall health and quality of life but also reduces reliance on medications, which can have adverse effects.

The pediatric segment is poised to hold a notable market share by 2032, backed by the improved awareness of disease and benefits of early diagnosis. Crohn's disease in pediatric patients presents unique challenges, including the need for treatments that are safe and effective for a developing body. Advances in research have led to tailored therapeutic approaches for children, including age-appropriate medications and nutritional interventions that address both growth and disease management. The growing emphasis on early intervention and personalized care is driving the demand for specialized treatments and support services for pediatric patients.

Asia Pacific Crohn's disease treatment market size will expand substantially through 2032, driven by increasing disease prevalence, improved healthcare infrastructure, and rising awareness of Crohn's disease across the region. The expansion of healthcare access and investment in medical technology are facilitating the availability of advanced treatment options, including biologics and targeted therapies. Additionally, a growing focus on R&D within the region is fostering innovation and enhancing the quality of care. As economic development continues and healthcare systems evolve, the Asia Pacific market is poised for substantial growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of crohn's disease
  - 3.2.1.2 Advancement in diagnostic techniques
  - 3.2.1.3 Increasing research & development activities for drug development
  - 3.2.1.4 Increased awareness about crohn's disease
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Complexity of disease management
  - 3.2.2.2 Lack of curative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 Anti-inflammatory agents
- 5.2.2 Immunosuppressants
- 5.2.3 Antibiotics and antipyretics
- 5.2.4 Other medications
5.3 Nutritional therapy
5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pediatric
7.3 Adult
7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & clinics
8.3 Homecare settings
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa